Oncopeptides AB

Equities

ONCO

SE0009414576

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:33 2024-05-24 EDT			5-day change	1st Jan Change
2.705 ^SEK	+0.37%		-2.70%	-64.69%

05-16	Oncopeptides AB Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress	CI
04-15	Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	CI

Oncopeptides AB Reports Earnings Results for the First Quarter Ended March 31, 2023

May 04, 2023 at 02:00 am

Oncopeptides AB (publ) reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was SEK 1.12 million. Net loss was SEK 71.03 million compared to SEK 98.59 million a year ago.

Latest news about Oncopeptides AB

Oncopeptides AB Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress	05-16	CI
Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	04-15	CI
Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	04-04	CI
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	03-27	CI
Oncopeptides Plans SEK300 Million Rights Issue to Support Multiple Myeloma Drug Commercialization	03-13	MT
Transcript : Oncopeptides AB, Q4 2023 Earnings Call, Feb 27, 2024	02-27
Oncopeptides AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27	CI
Oncopeptides AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Global markets live: Domino's Pizza, Walt Disney, Broadcom, Ryanair, Exxon Mobil, Goldman Sachs...	02-26
FDA Officially Withdraws Approval of Oncopeptides Pepaxto	02-23	DJ
Oncopeptides to Assess US FDA's Withdrawal of Blood Cancer Drug Approval	02-23	MT
Spanish Authority Gives Positive Recommendation for Pricing of Oncopeptides' Blood Cancer Drug	02-23	MT
Oncopeptides Receives Positive Recommendation for Pepaxti by Spanish Pricing Authority	02-23	CI
Oncopeptides Extends Exclusive Rights to Cancer Drug Until 2037	02-15	MT
Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines	12-15	CI
Oncopeptides' New CFO Takes Office	11-13	MT
Oncopeptides Selects to Present Additional Data from Ocean Study	11-13	CI
Oncopeptides AB Appoints Henrik Bergentoft as Chief Financial Officer	11-13	CI
Transcript : Oncopeptides AB, Q3 2023 Earnings Call, Nov 08, 2023	11-08
Oncopeptides AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Oncopeptides AB Announces the Nomination Committee	23-10-20	CI
Oncopeptides AB Announces Its Decision to Adopt the Application Process to Allow Pertide Access to Patients with Relapsed, Refractory Multiple Myeloma	23-09-28	CI
Oncopeptides AB(OM:ONCO) dropped from S&P Global BMI Index	23-09-18	CI
Oncopeptides Secures EU Committee Backing for Expanded Indication of Multiple Myeloma Therapy; Shares Surge	23-09-14	MT
Oncopeptides AB Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results	23-09-14	CI

Chart Oncopeptides AB

Duration

Period

More charts

Company Profile

Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Companyâs lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.

Sector

Biotechnology & Medical Research

Calendar

2024-05-25 - Controversies in Multiple Myeloma World Congress

More about the company

Income Statement Evolution

More financial data

Ratings for Oncopeptides AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ONCOPEPTIDES AB	-64.69%	55.73M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs